SEC61G identified as a pan-cancer biomarker and potential therapeutic target
SEC61G exhibits independent oncogenic functions across multiple cancers and serves as a prognostic biomarker.
Asset / Drug
Drug and asset intelligence for SEC61G with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.